ClinicalTrials.Veeva

Menu

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

G

Genrix (Shanghai) Biopharmaceutical

Status and phase

Active, not recruiting
Phase 2

Conditions

Allergic Rhinitis

Treatments

Biological: Placebo
Biological: GR1802 injection

Study type

Interventional

Funder types

Industry

Identifiers

NCT06315426
GR1802-011

Details and patient eligibility

About

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.

Enrollment

240 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Main Inclusion Criteria:

  1. Voluntarily sign the informed consent form.
  2. Seasonal allergic rhinitis has been prevalent for at least 2 years.
  3. Poor control of seasonal allergic rhinitis with nasal glucocorticoids or other therapeutic agents during the same pollen season in the past.
  4. Positive SPT or serum-specific IgE test results.
  5. Symptom severity scores for the season met the enrollment criteria.

Main Exclusion Criteria:

  1. Other nasal comorbidities or co-morbidities/states that may be present at the time of screening that affect efficacy determination.
  2. Subjects whose allergen exposures in their home or work environments may be expected to change significantly during the trial period.
  3. Subjects with poorly controlled recent asthma conditions.
  4. Presence of current or past history of infection of special concern, e.g., active tuberculosis, helminthic infections, severe herpes virus infections, etc.
  5. Previous use of anti-interleukin 4 receptor alpha subunit (IL4Rα) monoclonal antibody.
  6. Have a serious underlying medical condition that, in the opinion of the investigator, may pose a risk to subject safety by participation in a clinical trial.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

240 participants in 3 patient groups, including a placebo group

Interleukin-4 receptor responder 1
Experimental group
Treatment:
Biological: GR1802 injection
Interleukin-4 receptor responder 2
Experimental group
Treatment:
Biological: GR1802 injection
Placebo
Placebo Comparator group
Treatment:
Biological: Placebo

Trial contacts and locations

15

Loading...

Central trial contact

Xuewenjun Zhang, MD; Zheng Liu, PHD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems